Table: Towa Pharmaceutical - 6-MTH group results
Nov 13 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2023 Sep 30, 2022 Mar 31, 2024
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 107.40 90.50 216.30
(+18.7 pct) (+10.0 pct)
Operating 7.00 3.22 11.80
(+117.5 pct) (-68.8 pct)
Recurring 10.23 4.61 11.50
(+122.0 pct) (-64.6 pct)
Net 6.95 2.69 6.90
(+158.3 pct) (-70.9 pct)
EPS 141.26 yen 54.70 yen 140.18 yen
Ann Div 60.00 yen 60.00 yen
-Q2 div 30.00 yen 30.00 yen
-Q4 div 30.00 yen 30.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results